北京琮霖控股Orion获颁矿地具稀土勘探潜力

2014-09-12 07:23:00 来源：澳华财经在线 编辑：李钢 文章类型：原创

中资控股澳交所上市企业Orion金属公司（ASX：ORM）从昆州矿产资源部获得一块新的矿地勘探许可。

ACB News《澳华财经在线》报道，Orion 公司11日表示，新获采矿许可地由26个小区块构成，总面积78平方公里，处于Rockhampton采矿区，周围交通基建便利，距离格莱斯通矿产港口仅190公里。

更为重要的是，该矿地获颁标志着Orion新Ramsay项目的正式创立，矿区有着极具潜力的稀土元素（REE）探采目标，尤其是重稀土元素，另外，还可能存在特殊金属、铜、金矿脉。此前当地并无REE勘探历史。

Orion表示，如果从土地所有方顺利获得进入许可，预计可在本季度展开实地测勘。

去年Orion曾因全球大宗商品价格及需求持续低迷，从韩国两处稀土元素项目中撤资，上周还曾宣布退出Broughton溪项目，以重点推进西澳关键稀土元素项目Tanami West和昆州的基础金属项目。北京琮霖集团和琮霖集团董事长岳琮霖共持有其70.03%的股份。

（郑重声明：ACB News《澳华财经在线》对本文保留全部著作权限，转发时请标注来源）

Tags: ORM Orion 稀土 REE 北京琮霖集团

相关阅读

: ASIC警告养老金平台受托人加强风险管控否则将面临执法行动

澳大利亚证券及投资委员会（ASIC）周一发布《保障养老金——平台受托人对退休储蓄风险监控情况报告》（REP 833），告诫养老金平台（superannuation platform）受托人必须立即加强风险监控和治理，重点防范顾问收费异常、高风险养老金转移及异常资金流动等问题，否则将面临监管执法。

: 【异动股】碳酸锂价格回升带来扩张契机 Patagonia Lithium (ASX:PL3) Formentera锂卤水项目钻探备受关注年内飙升逾2倍

Patagonia Lithium Ltd (ASX股票代码:PL3)位于阿根廷北部“锂三角”地带的Formentera/Cilon锂卤水项目钻探进展备受市场关注，今年以来PL3创出233.33%涨幅，尽管并无消息披露，周三再度飙涨28.57%，周涨幅扩大至63.64%。

: From Demonstration to Commercialisation: Calix’s Industrial Decarbonisation Platform Accelerates Execution

Australian clean technology company Calix Limited (ASX: CXL) has released the first company newsletter of 2026. Managing Director and Chief Executive Officer Phil Hodgson said the company’s industrial decarbonisation platform technology is progressing from demonstration toward commercial execution, supported by advancing projects, growing revenues and disciplined cash management.

: “重量级一周”开启！美股科技巨头财报集中来袭业绩牵动市场神经

美股即将迎来本轮财报季中最具分量的一周。多家市值居前的科技巨头将在本周集中公布最新季度业绩，其结果被市场视为左右主要股指短期走向的关键变量。

: 【1.27】今日财经时讯及重要市场资讯

美股即将迎来本轮财报季中最具分量的一周。多家市值居前的科技巨头将在本周集中公布最新季度业绩，其结果被市场视为左右主要股指短期走向的关键变量。

: Strong China Demand Fuels Compumedics (ASX: CMP) Neuro-Imaging Growth New A$4.9m MEG Order from Beijing Normal University Lifts Total Orders to A$25m

ASX-listed medical technology company Compumedics Limited (ASX: CMP) announced on November 10 that it has secured a new A$4.9 million magnetoencephalography (MEG) system order from Beijing Normal University, lifting total contracted MEG revenues to about A$25 million. The deal strengthens the company’s leadership in Asia’s fast-growing neuro-imaging market and highlights robust demand from China’s expanding neuroscience sector.

: ImpediMed (ASX: IPD) Reports Record Q3 Performance; Commercial Momentum Builds and Shares Rebound

5 May 2025 | ACB News – Sydney，ImpediMed Limited (ASX: IPD), a leading Australian medical technology company, has reported record results for the third quarter of FY2025, ended 31 March. Key financial metrics reached new highs as the company continues to scale deployment of its SOZO® digital health platform in the U.S.

: A new platform suggests a new dimension of China's development

At a time when the global economic structure is undergoing profound adjustments and technological changes are accelerating, China is breaking through with a higher level of institutional opening.

免责声明：本网站信息仅供一般参考，不构成投资或财务建议。虽力求准确与完整，但不保证信息的准确性、完整性或时效性。投资有风险，决策前请咨询专业独立顾问。使用本网站即视为接受本免责声明。